---
{"dg-publish":true,"permalink":"/USMLE/Blood/Thrombotic thrombocytopenic purpura/","title":"Thrombotic thrombocytopenic purpura"}
---

# Etiology
---
ADAMTS13 deficiency
# Pathophysiology
---
>[!Mnemonic] 
>ADAMTS13 deficiency → excess vWF → microthrombus formation → blockage of small vessels → RBC fragmentation (hemolysis) and end-organ damage

TTP is a thrombotic microangiopathy, a condition in which microthrombi form and occlude the microvasculature. 
1. Autoantibodies or gene mutations → <span style="background:rgba(240, 200, 0, 0.2)">deficiency of ADAMTS13  (a metalloprotease that cleaves von Willebrand factor)</span>
2. ↓ Breakdown of vWF multimers → <span style="background:rgba(240, 200, 0, 0.2)">vWF multimers accumulate on endothelial cell surfaces </span>
3. <span style="background:rgba(240, 200, 0, 0.2)">Platelet adhesion and microthrombosis</span>
4. Microthrombi → fragmentation of RBCs with schistocyte formation → <span style="background:rgba(240, 200, 0, 0.2)">[[USMLE/Blood/Hemolytic anemia\|hemolytic anemia]]</span>
5. Arteriolar and capillary <span style="background:rgba(240, 200, 0, 0.2)">microthrombosis</span> → end-organ ischemia and damage, <span style="background:rgba(240, 200, 0, 0.2)">especially in the brain and kidneys</span> (potentially resulting in [[USMLE/Renal/Acute kidney injury\|acute kidney injury]] or stroke)



---
# Clinical features
- Fever
- <span style="background:rgba(240, 200, 0, 0.2)">Neurological signs and symptoms</span>
	- Altered mental status, [[USMLE/Psychiatry/Delirium\|delirium]]
	- Seizure, focal defects, stroke
	- Headache, dizziness
- <span style="background:rgba(240, 200, 0, 0.2)">Low platelet count (i.e. thrombocytopenia)</span>
	- Petechiae, purpura
	- Mucosal bleeding 
	- Prolonged bleeding after minor cuts
- <span style="background:rgba(240, 200, 0, 0.2)">Microangiopathic [[USMLE/Blood/Hemolytic anemia\|hemolytic anemia]]</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Fatigue, [[USMLE/Respiratory/Dyspnea\|dyspnea]], and pallor</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Jaundice</span>
- Impaired renal function
	- Hematuria, [[USMLE/Renal/Proteinuria\|proteinuria]]

>[!Mnemonic] 
>The typical patient is a previously healthy adult presenting with mental status changes, fever, petechiae, fatigue, and pallor. Laboratory tests will then indicate [[USMLE/Blood/Hemolytic anemia\|hemolytic anemia]] and possibly [[USMLE/Renal/Acute kidney injury\|acute kidney injury]] ([[USMLE/Renal/Acute kidney injury\|AKI]]). Impaired kidney function may not be present, and only a minority of patients will present with all five clinical findings.

---

<div class="transclusion internal-embed is-loaded"><a class="markdown-embed-link" href="/USMLE/Blood/Immune thrombocytopenia/#differential-diagnostics" aria-label="Open link"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="svg-icon lucide-link"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></a><div class="markdown-embed">



# Differential diagnostics

| Feature          | **Thrombotic Thrombocytopenic Purpura (TTP)**                                                                                                                          | **Immune Thrombocytopenia (ITP)**                                                                                                               |
| :--------------- | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :---------------------------------------------------------------------------------------------------------------------------------------------- |
| **Patho**        | ↓ ADAMTS13 activity → Large vWF multimers → microvascular platelet thrombi                                                                                             | Anti-platelet (anti-GpIIb/IIIa) Abs → splenic destruction of platelets                                                                          |
| **Presentation** | **Pentad (FAT RN):** **F**ever, **A**nemia (MAHA), **T**hrombocytopenia, **R**enal failure, **N**eurologic sx (e.g., confusion, stroke). Often acutely ill.            | Isolated mucocutaneous bleeding (petechiae, purpura, epistaxis). Often asymptomatic. No splenomegaly.                                           |
| **Labs**         | **MAHA** triad: **Anemia**, **Thrombocytopenia**, **Schistocytes** on smear. ↑LDH, ↑Bilirubin, ↓Haptoglobin. **Normal PT/PTT**. Dx confirmed by ADAMTS13 assay (<10%). | **Isolated thrombocytopenia** (<100,000/µL). Smear may show megathrombocytes. Otherwise normal CBC & smear. **Normal PT/PTT**. Dx of exclusion. |
| **Tx**           | **EMERGENT**. **Plasma exchange (PEX)** is first-line & life-saving. Corticosteroids, Rituximab. **Platelet transfusion is CONTRAINDICATED** (fuels thrombosis).       | **1st line:** Corticosteroids, IVIG. **2nd line:** Splenectomy, Rituximab, TPO-RAs (e.g., romiplostim). Observe if plt >30k & no bleeding.      |

![Pasted image 20230623160626.png](/img/user/appendix/Pasted%20image%2020230623160626.png)

</div></div>


---
# Treatment
*   **Medical Emergency:** TTP has a high mortality rate (>90%) if untreated. Do not delay treatment while awaiting confirmatory ADAMTS13 results.
*   <span style="background:rgba(240, 200, 0, 0.2)">**First-Line:** **Plasma exchange (PEX) / Plasmapheresis** is the cornerstone of treatment. It removes autoantibodies and ultra-large vWF multimers while replenishing functional ADAMTS13.</span>
*   **Immunosuppression:**
    *   **[[USMLE/Pharmacology/Corticosteroids\|Corticosteroids]]** (e.g., prednisone) are given with PEX to suppress autoantibody production.
    *   **Rituximab** (anti-CD20 monoclonal antibody) is increasingly used upfront or for refractory/relapsing disease to target B-cells.
*   **Adjunctive Therapy:**
    *   **Caplacizumab:** An anti-vWF nanobody that inhibits the interaction between vWF and platelets, leading to a faster rise in platelet count.
*   **AVOID:** Platelet transfusions are generally contraindicated as they can "fuel the fire" and worsen thrombosis, unless there is life-threatening bleeding.
